A Quarter Century with Mr. Hageman^[*]

Keywords

Hageman factor - Factor XI - Plasma prekallikrein - High molecular weight kininogen

^* The 1979 Wright-Schulte Lecture of the International Society for Thrombosis and Haemostasis. Otherwise unpublished studies were supported in part by Grant HL-01661 from the National Heart, Lung and Blood Institute, the National Institutes of Health, U.S. Public Health Service, and in part by grants from the American Heart Association and its Northest Ohio Affiliate. Plenary lecture held at the VIIth International Congress on Thrombosis and Haemostasis, London, 15-20 July, 1979.

• References

• 1 Ratnoff OD, Hartmann RC, Conley CL. Studies on a proteolytic enzyme in human plasma. V. The relationship between the proteolytic activity of plasma and blood coagulation. J Exp Med 1950; 91: 123-133
• 2 Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 603-613
• 3 Margolius Jr AJ, Ratnoff OD. Observations on the hereditary nature of Hageman trait. Blood 1956; 11: 565-569
• 4 Bennett B, Ratnoff OD, Holt JB, Roberts HR. Hageman trait (factor XII deficiency): a probable second genotype inherited as an autosomal dominant characteristic. Blood 1972; 40: 412-415
• 5 Smink McL M, Daniel TM, Ratnoff OD, Stavitsky AB. Immunologic demonstration of a deficiency of Hageman factor-like material in Hageman trait. J Lab Clin Med 1967; 69: 819-832
• 6 Saito H, Scott JG, Movat HZ, Scialla SJ. Molecular heterogeneity of Hageman trait (factor XII deficiency): evidence that 2 of 49 cases are cross-reacting material positive (CRM⁺). J Lab Clin Med 1979; 94: 256-265
• 7 Glueck HI, Roehill Jr W. Myocardial infarction in a patient with Hageman (factor XII) defect. Ann Int Med 1966; 64: 390-396
• 8 Hoak JC, Swanson LW, Warner ED, Connor WE. Myocardial infarction associated with severe factor-XII deficiency. Lancet 1966; 2: 884-886
• 9 Ratnoff OD, Busse Jr RJ, Sheon RP. The demise of John Hageman. New Engl J Med 1968; 279: 760-761
• 10 Donaldson VH, McAdams AJ, Stratman EJ, Glueck HI. Fatal vascular disease in a patient with Hageman trait and a connective tissue disorder. New Engl J Med 1977; 297: 1237 (letter)
• 11 Biggs R, Sharp AA, Margolis J, Hardisty RM, Stewart J, Davidson WM. Defects in the early stages of blood coagulation: a report of four cases. Brit J Haem 1958; 4: 177-191
• 12 Soulier J-P, Prou-Wartelle O. New data on Hageman factor and plasma thromboplastin antecedent: the role of 'contact' in the initial phase of blood coagulation. Brit J Haemat 1960; 6: 88-101
• 13 Ratnoff OD, Rosenblum JM. Role of Hageman factor in the initiation of clotting by glass. Amer J Med 1958; 25: 160-168
• 14 Schiffman S, Rapaport SI, Ware AG, Mehl JW. Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma. Proc Soc Exp Biol Med 1960; 105: 453-455
• 15 Kraut H, Frey EK, Bauer E. Über ein neues Kreislaufhormon. II. Mitteilung. Hoppe-Seylers Zeitschr. Physiol. Chem 1928; 175: 97-114
• 16 Vogt W. Demonstration of the presence of two separate kininforming systems in human and other plasma. In Erdos EG, Back N, Sicuteri F. "Hypotensive Peptides,". New York: Springer Verlag: 1966. pp 185-192
• 17 Jacobsen S, Kriz M. Some data on two purified kininogens from human plasma. Brit J Pharmacol 1967; 29: 25-36
• 18 Margolis J. Plasma pain-producing substance and blood clotting. Nature (London) 1957; 180: 1464-1465
• 19 Webster ME, Ratnoff OD. Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature (London) 1961; 192: 180-181
• 20 Ratnoff OD. The effect of clotting on the spontaneous activation of plasmin. J Clin Invest 1955; 34: 958-959 (abstr.)
• 21 Niewiarowski S, Prou-Wartelle O. Rôle du facteur contact (facteur Hageman) dans la fibrinolyse. Thromb Diath Haemorrh 1959; 3: 593-603
• 22 Iatridis SG, Ferguson JH. Effect of surface and Hageman factor on the endogenous or spontaneous activation of the fibrinolytic system. Thromb Diath Haemorrh 1961; 6: 411-423
• 23 Ogston D, Ogston CM, Ratnoff OD, Forbes CD. Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest 1969; 48: 1786-1801
• 24 Kaplan AP, Austen KF. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med 1972; 136: 1378-1393
• 25 Laake K, Vennerod AM. Factor XII-induced fibrinolysis: studies on the separation of prekallikrein, plasminogen proactivator, and factor XI in human plasma. Thromb Res 1974; 4: 285-302
• 26 Bouma BM, Griffin JH. Human prekallikrein (plasminogen proactivator): purification, characterization and activation by activated factor XII. Thromb Haemostasis 1977; 38: 136 (abstr.)
• 27 Vennerod AM, Laake K. Prekallikrein and plasminogen proactivator: absence of plasminogen proactivator in Fletcher factor deficient plasma. Thromb Res 1976; 8: 519-522
• 28 Mandle Jr R, Kaplan AP. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 1977; 252: 6097-6104
• 29 Saito H. The participation of plasma Thromboplastin antecedent in contact mediated fibrinolysis. Proc Soc exp Biol (in press)
• 30 Goldsmith Jr GH, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest 1978; 62: 54-60
• 31 Schiffman S, Lee P. Partial purification and characterization of contact activation cofactor. J Clin Invest 1975; 56: 1082-1093
• 32 Schiffman S, Lee P. Preparation, characterization, and activation of a highly purified factor XI: evidence that a hitherto unrecognized plasma activity participates in the interaction of factors XI and XII. Brit J Haemat 1974; 27: 101-114
• 33 Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood 1965; 26: 521-532
• 34 Waldman R, Abraham JP, Rebuck JW, Caldwell J, Saito H, Ratnoff OD. Fitzgerald factor: a hitherto unrecognized clotting factor. Lancet 1975; 1: 949-951
• 35 Saito H, Ratnoff OD, Waldmann R, Abraham JP. Fitzgerald trait. Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis, generation of kinins, and the property of diluted plasma enhancing vascular permeability. J Clin Invest 1975; 55: 1082-1089
• 36 Wuepper KD. Biochemistry and biology of components of the plasma kinin-forming system. In: Lepow IH, Ward PA. "Inflammation: Mechanisms and Control,". New York: Academic Press: 1972. pp. 93-117
• 37 Wuepper KD, Miller DR, Lacombe M-J. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-1672
• 38 Donaldson VH, Glueck HI, Miller MA, Movat HA, Habal F. Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med 1976; 87: 327-337
• 39 Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-1662
• 40 Saito H, Ratnoff OD. Molecular heterogeneity of human plasma prekallikrein deficiency (Fletcher trait). Clin Res 1977; 25: 347 A
• 41 Donaldson VH, Ratnoff OD. Hageman factor: alterations in physical properties during activation. Science 1965; 150: 754-756
• 42 Schoenmakers JG G, Matze R, Haanen C, Zilliken F. Hageman factor, a novel sialoglycoprotein with esterase activity. Biochem Biophys Acta 1965; 101: 166-176
• 43 Revak SD, Cochrane CP, Johnston AR, Hugli TE. Structural changes accompanying enzymatic activation of human Hageman factor. J Clin Invest 1974; 54: 619-627
• 44 Kaplan AP, Austen KF. A pre-albumin activator of prekallikrein. J Immunol 1970; 105: 802-811
• 45 Fujikawa K, Walsh KA, Davie EW. Isolation and characterization of bovine factor XII (Hageman factor). Biochem 1977; 16: 2270-2278
• 46 Fujikawa K, Kurachi K, Davie EW. Characterization of bovine factor XII_a (activated Hageman factor). Biochem 1977; 16: 4182-4188
• 47 Ratnoff OD, Crum JD. Activation of Hageman factor by solutions of ellagic acid. J Lab Clin Med 1964; 63: 359-377
• 48 Hardisty RM, Margolis J. The role of Hageman factor in the initiation of blood coagulation. Brit J Haemat 1959; 5: 203-211
• 49 Vroman L. Effect of hydrophobic surfaces upon blood coagulation. Thromb Diath Haemorrh 1964; 10: 455-493
• 50 McMillin CR, Saito H, Ratnoff OD, Walton AG. The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. J Clin Invest. 1974; 54: 1312-1322
• 51 Fair BD, Saito H, Ratnoff OD, Rippon WB. Detection by fluorescence of structural changes accompanying the activation of Hageman factor (factor XII). Proc Soc Exp Biol Med 1977; 155: 199-202
• 52 Revak SD, Cochrane CG, Griffin JH. The binding and cleavage characteristics of human Hageman factor during deficient in factor XI, prekallikrein, or high molecular weight kininogen. J Clin Invest 1977; 59: 1167-1175
• 53 Ratnoff OD, Saito H. Amidolytic properties of single-chain activated Hageman factor. Proc Natl Acad Sci USA 1979; 76: 1461-1463
• 54 Ratnoff OD, Saito H. Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen and plasma thromboplastin antecedent. Proc Natl Acad Sci USA 1979; 76: 958-961
• 55 Saito H. Purification of high molecular weight kininogen and the role of this agent in blood coagulation. J Clin Invest 1977; 60: 584-594
• 56 Schiffman S, Lee P, Waldmann R. Identity of contact activation cofactor and Fitzgerald factor. Thromb Res 1975; 6: 451-454
• 57 Wiggins RC, Bouma BN, Cochrane CG, Griffin JH. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc Natl Acad Sci 1977; 74: 4636-4640
• 58 Donaldson VH, Kleniewski J, Saito H, Sayed JK. Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma. J Clin Invest 1977; 60: 571-583
• 59 Mandle RJ, Coleman RW, Kaplan AP. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-4183
• 60 Thompson RE, Mandle Jr R, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60: 1376-1380
• 61 Ratnoff OD, Saito H. Evidence that Fitzgerald factor counteracts inhibition by kaolin or ellagic acid of the amidolytic properties of a plasma kallikrein. Blood 1976; 47: 243-251
• 62 Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med 1973; 138: 1564-1583
• 63 Ratnoff OD, Saito H. The countervailing effect of high molecular weight (HMW) kininogen upon inhibition by kaolin of Hageman factor (factor XII, HF) and HF fragments (HF_f). Blood 52, Suppl 1978; 1: 351 (abstr.)